- Home
- ADBE vs AMGN Comparison
ADBE vs AMGN Comparison
Compare ADBE & AMGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADBE
- AMGN
- Stock Information
- Founded
- ADBE 1982
- AMGN 1980
- Country
- ADBE United States
- AMGN United States
- Employees
- ADBE 30709
- AMGN N/A
- Industry
- ADBE Computer Software: Prepackaged Software
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ADBE Technology
- AMGN Health Care
- Exchange
- ADBE Nasdaq
- AMGN Nasdaq
- Market Cap
- ADBE 164.4B
- AMGN 156.2B
- IPO Year
- ADBE 1986
- AMGN N/A
- Fundamental
- Price
- ADBE $385.71
- AMGN $306.95
- Analyst Decision
- ADBE Buy
- AMGN Buy
- Analyst Count
- ADBE 24
- AMGN 21
- Target Price
- ADBE $549.55
- AMGN $323.26
- AVG Volume (30 Days)
- ADBE 4.5M
- AMGN 3.0M
- Earning Date
- ADBE 03-12-2025
- AMGN 05-01-2025
- Dividend Yield
- ADBE N/A
- AMGN 3.10%
- EPS Growth
- ADBE 44.74
- AMGN N/A
- EPS
- ADBE 15.16
- AMGN 7.56
- Revenue
- ADBE $22,037,000,000.00
- AMGN $33,424,000,000.00
- Revenue This Year
- ADBE $11.44
- AMGN $7.36
- Revenue Next Year
- ADBE $10.12
- AMGN $2.18
- P/E Ratio
- ADBE $25.43
- AMGN $40.60
- Revenue Growth
- ADBE 10.54
- AMGN 18.57
- 52 Week Low
- ADBE $374.50
- AMGN $253.30
- 52 Week High
- ADBE $587.75
- AMGN $346.85
- Technical
- Relative Strength Index (RSI)
- ADBE 35.42
- AMGN 47.38
- Support Level
- ADBE $382.45
- AMGN $304.29
- Resistance Level
- ADBE $404.50
- AMGN $317.58
- Average True Range (ATR)
- ADBE 11.83
- AMGN 5.64
- MACD
- ADBE -0.79
- AMGN -2.39
- Stochastic Oscillator
- ADBE 16.15
- AMGN 13.44
About ADBE Adobe Inc.
Adobe provides content creation, document management, and digital marketing and advertising software and services to creative professionals and marketers for creating, managing, delivering, measuring, optimizing, and engaging with compelling content multiple operating systems, devices, and media. The company operates with three segments: digital media content creation, digital experience for marketing solutions, and publishing for legacy products (less than 5% of revenue).
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.